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Background: Little is known about the change in prevalence of comorbidities during the 
disease course of people with multiple sclerosis (MS) and whether the prevalences vary by MS 
onset-type. 
Objective: To calculate the change in prevalence of comorbidities between symptom onset and 
the time of study, to compare the prevalences of comorbidities with those in the Australian 
population at the time of study and to examine onset-type differences. 
Methods: Comorbidity data from 1,518 participants of the Australian MS Longitudinal Study 
and Australian population comparator data (2014-15 National Health Survey) were used. The 
change in prevalence between time points and prevalence ratios (PR) at the time of study 
(crude, age-and-sex adjusted, and stratified by onset-type) were calculated. 
Results: Comorbidities were common, and those with the largest increases in prevalence 
between MS symptom onset and the time of study were depression (+26.9%), anxiety 
(+23.1%), hypertension (+21.9%), elevated cholesterol (+16.3%), osteoarthritis (+17.1%), eye 
diseases (+11.6%), osteoporosis (+10.9%) and cancer (+10.3%). Compared to the general 
population and after age-and-sex adjustment, participants had a significantly higher prevalence 
for 14/19 comorbidities at the time of study. The associations were strongest for anaemia, 
cancer (both PR>4.00), anxiety, depression, migraine (all PR>3.00), psoriasis and epilepsy 
(both PR>2.00). No significant differences were seen by onset-type. 
Conclusion: Comorbidities are common at MS symptom onset and increase with MS duration. 
Having MS may thus contribute to accrual of comorbidities. This emphasises the importance 
of optimal screening for and management of comorbidities in early MS and throughout the 
disease course. 
 





As there is still no known cure for multiple sclerosis (MS), current treatment mainly focuses 
on preventing relapses and disability progression as well as improving other health outcomes 
of people with MS (PwMS) [1]. However, MS-related outcomes are highly heterogeneous 
[2,3]. Comorbidities, the medical conditions that co-occur with an index disease [4], may 
explain part of the heterogeneity of clinical outcomes in MS. Comorbidities have recently 
engendered substantial research interest in MS because their presence can cause diagnostic 
delays, alter disability progression, limit physical activities [5], increase MS symptoms severity 
[6], lower quality of life [7], and affect MS treatment utilization and mortality [8].  
Comorbidities are common in chronic diseases like MS and their accumulation over time 
complicates disease management. However, no study has focused on identifying comorbidities 
with increases in prevalence after MS symptom onset. Most studie-009is have examined the 
prevalence of comorbidities of PwMS cross-sectionally during the course of MS, generally 
finding a higher prevalence in PwMS of most diseases compared to controls [9-12]. Other 
studies focused on the time before and at MS onset, finding that the prevalence of  hypertension, 
inflammatory bowel disease (IBD), high cholesterol [13], asthma [14], anaemia, thyroid 
disorders, epilepsy, migraine, any mood or anxiety disorders and depression [15,13] were 
already more common before or at MS symptom onset compared to controls. In one study, 
comorbidities were already common five years before MS onset and became more prevalent at 
the time of symptom onset [16]. Two longitudinal studies found that after MS diagnosis, PwMS 
were at greater risk of cardiovascular diseases compared to healthy controls [17,18]. A good 
understanding of how the prevalence of comorbidities changes at these critical time points and 
which comorbidities are more common is important to better improve health outcomes. 




Furthermore, the last two decades showed dramatic progress for people with relapsing 
remitting MS in terms of risk factors and therapies [19,20]. For all the success in relapsing 
remitting MS, the story in progressive MS is more challenging. Previous research comparing 
the differences in characteristics and epidemiological features between relapse-onset and 
progressive-onset MS is limited and no study has yet compared the different effects on the 
prevalence of comorbidities between these two onset-types.  
The aims of our study were to: (a) determine the change in prevalence of comorbidities between 
MS symptom onset and at the time of study (on average 20.5 years post-symptom onset) among 
the Australian MS Longitudinal Study (AMSLS) participants; (b) compare the prevalence of 
comorbidities at the time of study to the general Australian population, and; (c) examine 




The study sample was recruited from the AMSLS database, a large, national sample of around 
3,000 adult Australian volunteers with MS [21]. An estimated 96% of the participants were 
diagnosed by a neurologist with definite MS using the McDonald Criteria [22,23]. It is an 
ongoing survey-based research project supported by MS societies in all Australian states and 
territories. Ethical approval was initially given by the Australian Capital Territory Health 
Human Research Ethics Committee (HREC) and by the Tasmanian Health and Medical HREC 
when the study centre was relocated to Tasmania in 2014 [21].   Written informed consent 
forms for the survey were provided by each participant. In August to October 2016, a total of 




3,112 active participants were invited to complete the AMSLS Lifestyle and Environment 
Survey of whom 1,518 (49%; 1,067 online and 451 paper-based) responded to the survey. 
As a direct comparator, we used the 2014-15 National Health Survey (2014-15 NHS) 
conducted by the Australian Bureau of Statistics from July 2014 to June 2015 [24].  Detailed 
information about the 2014-15 NHS design, methodology and interpretation of results has been 
published [24]. In brief, a total sample of 19,259 (82% response rate) Australians were 
randomly selected from all states and territories to assess their health status and health-related 
aspects of their lifestyles [24]. Estimates from the survey were obtained using a complex 
weighting and estimation procedure to ensure that results from sample survey infer results for 
the in-scope total population by state, age and sex [11,24].  Data on major long-term health 
conditions (number of people with the medical condition and total number of respondents) 
were extracted in 10-year age groups (<35, 35-44, 45-54, 55-64, 65-74 and 75 years and over) 
and stratified by sex.  
Measurements 
Comorbidities 
Participants were asked about the presence of 30 comorbidities that have been previously 
frequently reported in prior comorbidity studies in MS [9,25,26]. For each comorbidity, we 
asked “Do you have or have you had this condition?” (Yes/No). If yes, the participant was 
coded as having that comorbidity at the time of study and we asked, “Did you have this before 
your first symptom of MS?” (yes/no/don’t know). If yes, the participant was coded as having 
the comorbidity at MS symptom onset. The “Don’t know” group was combined with the “No” 
group. The number of comorbidities for the total cohort, for those with relapse-onset and 
progressive-onset MS at these two time points were calculated. To make appropriate 
comparisons with the comorbidities reported in the 2014-15 NHS, we: 1) excluded 
comorbidities that were not included in the 2014-15 NHS (other autoimmune disorders, 




Parkinson’s disease, systemic lupus erythematosus) or not assessed in a similar fashion in both 
surveys (eye diseases, allergies); 2) re-grouped or combined some comorbidities to match the 
2014-15 NHS disease categories (as described in Figure 1 footnotes) and 3) excluded 
comorbidities that had <10 participants (chronic renal disease) in order to have sufficient power 
for the analysis. We were left with 19 comorbidities for the prevalence ratio analysis (Figure 
1).  
Other measures 
MS duration was calculated by subtracting the year of MS symptom onset from the year of 
survey. Age at symptom onset was calculated by subtracting the year of MS symptom onset 
from the year of birth. Data on age, sex, MS onset-type (i.e. relapse-onset and progressive-
onset), disease modifying therapy (DMT) status and education attainment were also obtained 
from the survey. 
Statistical analysis 
We used descriptive statistics to examine the demographics of the MS cohort and the 2014-15 
NHS. The characteristics of the study sample were compared to the participants who were 
invited but not included in the study to ascertain the generalisability across the sample. We 
calculated the crude prevalence of each comorbidity at MS symptom onset and at the time of 
completing the 2016 Lifestyle and Environment Survey (i.e. at the time of study) and calculated 
the change between those two time points.  
To compare the prevalence of comorbidities between our MS cohort and the general Australian 
population, we calculated the crude prevalence of the 19 comorbidities in the MS cohort at the 
time of study and the crude prevalence of that comorbidity in the general Australian population. 
This process was repeated for each sex and age category. Using this dataset of rates for each 




sex and age category in the two cohorts, we used Poisson regression to adjust the prevalence 
ratio (PR) for sex and age at the time of study.  
We then stratified the comorbidity data by MS onset-type (i.e. relapse-onset vs progressive-
onset) and calculated the crude prevalence of each comorbidity at MS symptom onset and at 
the time of study. To compare the prevalence of comorbidities between people with relapse-
onset MS and people with progressive-onset MS, we calculated the crude prevalence of each 
comorbidity in the relapse-onset cohort at both time points and the crude prevalence of that 
comorbidity in the progressive-onset cohort. After obtaining a dataset of rates for each sex and 
age category in the two cohorts, we used Poisson regression to adjust the prevalence ratio (PR) 
for age and sex between both time points, respectively. To further examine whether the PR of 
both MS onset-types differed from the general Australian population at the time of study, we 
repeated the analysis above and calculated the p-values of interaction by including product 
terms in our model. 
We limited all PR analyses to those comorbidities that had 10 or more participants to have 
sufficient power. All analyses were performed using STATA/IC for Windows (version 15.0; 
StataCorp LP, College Station, Texas, USA). The significance level was set at 95% confidence 




Of the MS cohort, 79.6% were female (vs 50.8% of the 2014-15 NHS participants), 88.1% had 
relapse-onset MS and 62.4% were currently taking disease modifying therapy (Table 1). The 
mean age of all included participants at symptom onset was 36.0 years while the mean age at 
the time of study was 55.7 years. Almost 37% of the MS cohort had bachelor’s and 




postgraduate degree (vs 28% of the 2014-15 NHS participants). Overall, 65.3% of the 
participants reported at least one comorbidity at symptom onset and 90.0% at the time of study. 
The participants included in this analysis had a similar sex distribution (female 79.5% vs 
77.2%; p=0.10) and education attainment (37% with bachelor’s or postgraduate degree vs 34%; 
p=0.11) compared to participants who were not included. Included participants were slightly 
older (+1.49 years, p <0.01) and had a longer MS duration since MS diagnosis (+0.56 years, 
p=0.04).  
Prevalence of comorbidities at MS symptom onset vs at the time of the study  
Table 2 gives the prevalence of all thirty comorbidities assessed.  At symptom onset, the most 
prevalent comorbidities were allergies (29.2%), migraine (20.2%), anxiety (15.9%), depression 
(15.8%), hypertension (8.3%), high cholesterol (7.2%) and anaemia (7.2%) (Table 2). At the 
time of study (on average 20.5 years post-symptom onset), the most prevalent comorbidities 
were depression (42.7%), anxiety (39.0%), allergies (37.4%), hypertension (30.2%), migraine 
(28.1%), high cholesterol (23.5%) and osteoarthritis (23.3%). The comorbidities with the 
highest change in prevalence from symptom onset to the time of study were depression 
(+26.9%), anxiety (+23.1%), hypertension (+21.9%), osteoarthritis (+17.1%), high cholesterol 
(+16.3%), eye diseases (+11.6%), osteoporosis (+10.9%) and cancer (+10.3%). 
Prevalence ratios of comorbidities at the time of the study 
Compared to the general Australian population and after age-and-sex adjustment, PwMS had 
a significantly higher prevalence of most comorbidities (14/19) at the time of study (Figure 1). 
The associations were strongest for anaemia, cancer (both PR>4.00), anxiety, depression, 
migraine (all PR>3.00), psoriasis and epilepsy (both PR>2.00). The participants were less 
likely to have type 1 diabetes compared to the general Australian population (PR=0.63). 
Prevalence and Prevalence ratios by MS onset-type  




Compared to progressive-onset MS and after age and sex adjustment, the prevalence of 
comorbidities in people with relapse-onset MS were not significantly different at MS symptom 
onset (Table 3). At the time of study and after age adjustment, people with relapse-onset MS 
were significantly more likely to have allergies compared with progressive-onset MS. There 
were no other statistically significant associations. Similarly, compared to the general 
Australian population and after age-and-sex adjustment, the participants had no significant 
differences in prevalence ratios of comorbidities when stratified by MS onset-type at the time 
of study (Table 4).  
 
Discussion 
The present study comprehensively examined the changes in the prevalence of a wide range of 
comorbidities between symptom onset and at the time of study using a large sample of 
Australians with MS and determined the effects of MS onset-types on the prevalence of their 
comorbidities. In this MS cohort, comorbidities were already prevalent at MS symptom onset, 
but the prevalence was substantially higher a mean of 20.5 years after symptom onset. At this 
time, 14 out of 19 comorbidities were significantly more common in PwMS compared to the 
general population. Having MS may contribute to the risk of accrual of comorbidities or there 
may be shared pathogeneses and/or risk factors between MS and other diseases. Regardless of 
the reason, these findings suggest that early identification of comorbidities and minimising the 
development of new comorbidities throughout the disease process is an important 
consideration in the management of people with MS. The lack of significant differences by MS 
onset-type suggests that the management and screening for comorbidities is equally important 
in both onset-types.  




Mental health and physical comorbidities were already prevalent at the time of onset (65.3% 
with >1 comorbidity), with the most common comorbidities being allergies (29.2%), migraine 
(20.2%), anxiety (15.9%), depression (15.8%), hypertension (8.3%), high cholesterol (7.2%) 
and anaemia (7.2%). A high prevalence of comorbidities is consistent with previous literature 
[27,13], and is associated with a longer time to diagnosis, higher disability level at MS 
diagnosis and faster disability progression over time [3]. It is therefore important that clinicians 
are aware of the presence of any of these comorbidities at the diagnosis of a first demyelinating 
event and treat the patient holistically with these comorbidities in mind. They may also consider 
screening for (additional) comorbidities or the risk factors of comorbidities as soon as practical. 
Useful documents to guide clinicians on screening and management practices include the 
National Institute for Health and Care Excellence (NICE) guidelines on multimorbidity [28] 
and a Clinical Resource Guide on comorbidities in Multiple Sclerosis [29].  
At a mean of 20.5 years post-symptom onset, the prevalence of comorbidities increased, with 
90% of the participants having at least one comorbidity. The largest increases in prevalence 
were seen for depression (+26.9%), anxiety (+23.1%), hypertension (+21.9%), osteoarthritis 
(+17.1%), high cholesterol (+16.3%), eye diseases (+11.6%), osteoporosis (+10.9%) and 
cancer (+10.3%). Importantly, 14/19 comorbidities were more common in PwMS than in the 
general population, with the strongest effect sizes for anaemia, cancer, anxiety, depression, 
migraine, psoriasis and epilepsy.  As these comorbidities contribute to a poorer MS prognosis 
[30,3], and substantially lower quality of life [31], it is pertinent to try to prevent the 
development of these comorbidities. This could be achieved by optimising the lifestyle of 
PwMS where possible and evaluating drug choices that may put them at an additional risk of 
comorbidities. Further, clinicians may consider assessing comorbidity risk factors and screen 
for new comorbidities throughout the disease course. Also, optimal management of MS and 
comorbidities that focuses on an improvement or maintenance of daily function and quality of 




life is likely to have positive impacts on healthy lifestyle behaviours [30]. In Australia, MS 
Nurses play an important role in educating PwMS around the management of symptoms and 
relapses, healthy lifestyle behaviour, and other aspects of overall wellbeing. The MS Brain 
Health project also contain useful resources for clinicians, MS Nurses and PwMS [32].  
There are several explanations for why many comorbidities may be prevalent at MS symptom 
onset. First, the comorbidity may be a preclinical symptom of MS. For instance, the high 
prevalence of depression and anxiety at MS symptom onset has been previously observed in 
PwMS, suggesting that these symptoms could be among the first clinical signs of MS resulted 
from immunological and inflammatory changes in the brain [33].  Second, a comorbidity and 
MS may have overlapping pathogeneses. For example, migraine could be contributing to MS 
by changing cytokine expressions or increasing blood brain barrier permeability thereby 
predisposing the individual to having an autoimmune reaction and potentially accelerating 
demyelination in the central nervous system [34]. Last, a comorbidity and MS may share some 
of the same risk factors.  For example, anaemia and MS are both common in young adult 
women [35], and the prevalence of psoriasis has been shown to be higher with increasing 
distance from the equator, potentially indicating that low ultraviolet radiation exposure may be 
a shared risk factor [36].  
With the prevalence of most comorbidities substantially higher at the time of study and the 
prevalence for many significantly higher than the general population, the accumulation of 
comorbidities seems to be beyond normal aging. There may be several reasons for this. First, 
having MS changes lifestyle behaviours. For example, the physical activity levels of PwMS 
are on average one standard deviation lower than the general population [37], which may 
contribute to an increased risk in dyslipidaemia, vascular comorbidities [38,39] and 
osteoporosis [40]. Second, the use of DMTs in people with MS may be associated with an 




increased risk of developing or worsening of existing comorbidities. For example, fingolimod 
is contraindicated for PwMS who had recent cardiovascular problems such as hypertension and 
hypercholesterolemia [41], while others reported hypertension after natalizumab infusions 
[42]. Likewise, hypertension is  reported in 10% and 4.3% of PwMS treated with glatiramer 
acetate and teriflunomide, respectively [42]. Further, interferons are associated with 
developing depression [43] and worsening of headache in more than 50% of people with MS 
with pre-existing headache [44]. It is also important to note that in most cases and as part of 
clinical practice, the development or worsening of these comorbidities usually result in a 
change in DMT to mitigate the risk and the long-term effects of these DMTs on comorbidity 
burden. Last, MS and comorbidities may have shared risk factors or pathologies that put PwMS 
at higher risk of accumulating comorbidities. For example, the association between MS and 
cancer, epilepsy, stomach or thyroid disorders is thought to be a reflection of common genetic, 
disease or environmental risk factors [13,45].  
We did not identify any differences by MS onset-type. We and others have previously shown 
that people with progressive-onset MS are worse off in terms of patient-reported clinical 
outcomes [46] and disability progression [47] compared to people with relapse-onset MS. 
However, our data do not show that people with progressive-onset MS have a higher prevalence 
at onset or time of study compared to those with relapsing-onset MS, or that the prevalence 
ratio of comorbidities compared to the general population differed by MS onset type. We were 
not able to make comparisons for comorbidities that were not sufficiently prevalent in the 
progressive-onset MS cohort. Despite that, our data seem to suggest that screening and 
management for comorbidities in PwMS does not need to differ by onset-type.  
A key strength of our study is that it is population-based and has been shown to be a 
representative of the MS population [21]. Despite that, some selection bias may have occurred 




as only half of the invited active AMSLS participants responded to the survey. Those who 
participated were slightly older, which should not have affected our prevalence ratio estimates 
since our data were age-adjusted but could have increased the prevalence estimates somewhat. 
Another strength was that we estimated the prevalence at two important time points using the 
same MS cohort. We also included a wide range of comorbidities rather than mainly focusing 
on some comorbidity groups as in the previous studies [48,49]. A limitation is that the 
comorbidities were self-reported, which may have resulted in recall bias or some 
misclassification or measurement error, specifically for comorbidities at MS symptom onset. 
Further, ascertainment bias may have occurred, as some comorbidities may be more or less 
frequently diagnosed after MS symptom onset because PwMS regularly see a neurologist or 
other healthcare professionals. This may have been a contributing factor to the high prevalence 
ratios seen for migraines, epilepsy, depression and anxiety (detection bias) or low prevalence 
ratios for heart disease, stroke and vascular diseases due to more prevention opportunities after 
diagnosis (surveillance bias). Also, although we adjusted for age and sex, there may be other 
confounders such as education, ethnicity, income or treatment methods that were not 
considered and could have impacted the prevalence ratio estimates. Lastly, given we did not 
have individual level data of the 2014-15 NHS, we were not able to exclude PwMS in the 2014-
15 NHS. However, it would have only included approximately 20 people with MS out of the 
19,259 NHS participants, based on 2017 MS prevalence estimates [50].   
Comorbidities are already prevalent in the early stages of MS and having MS may also 
contribute to accrual of comorbidities. Our findings support the need for optimal screening, 
prevention of and managing comorbidities from early MS independent of onset type and 
continuously throughout the disease course as this has the potential to make an impact on the 
overall MS outcomes.  
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Table 1. Characteristics of people with Multiple Sclerosis (MS) and the Australian populationa 
Characteristics Total study sample 
MS onset-type of study 
sampleb Australian 
population 
 Relapse-onset MSc 
Progressive-
onset MSd 
Total, n (%) 1,518  1,113 (88.1) 150 (11.9) 17,733,300 
Sex, n (%) 
         Male 309 (20.4) 190 (17.1) 64 (42.7) 8,724,300 (49.2) 
         Female 1204 (79.6) 919 (82.9) 86 (57.3) 9,006,600 (50.8) 
Currently on disease modifying therapy, n 
(%)  759 (62.4) 637 (67.7) 35 (28.9) - 
Age at symptom onset (years), 
mean (SD) 36.0 (10.8) 35.9 (10.4) 40.3 (11.4) - 
Years since MS symptom onset, 
 mean (SD) 20.5 (10.9) 20.1 (10.6) 22.3 (11.4) - 
Age at the time of study, mean (SD) 55.7 (11.2) 55.0 (11.2) 62.3 (9.3) - 
Age groups at the time of study (years), n (%) 
         <35 48 (3.2) 38 (3.5) 0 (0.0) 5,553,600 (31.3) 
         35-44 226 (15.1) 183 (16.6) 5 (3.4) 3,167,100 (17.9) 
         45-54 374 (25.0) 276 (25.1) 29 (19.7) 3,056,500 (17.2) 
         55-64 507 (33.8) 379 (34.4) 45 (30.6) 2,669,600 (15.1) 
         65-74 300 (20.0) 199 (18.1) 58 (39.5) 1,937,700 (10.9) 
          >75 44 (3.0) 26 (2.4) 10 (6.8) 1,348,800 (7.6) 
Education attainment, n (%) 
        Secondary school or less 356 (29.3) 239 (25.3) 55 (45.5) 6,232,000 (35.6) 
        Occupational certificate/diploma 415 (34.2) 336 (35.6) 36 (29.8) 6,431,300 (36.7) 
        University degree and higher 443 (36.5) 370 (39.2) 30 (24.8) 4,840,300 (27.7) 
Number of comorbidities at MS symptom onset, n (%) 
         0 538 (34.8) 365 (33.8) 60 (40.0) - 
         1 431 (28.4) 338 (30.4) 29 (19.3) - 
       >2 559 (36.9) 410 (36.8) 61 (40.7) - 
Number of comorbidities at the time of study, n (%) 
         0 151 (10.0) 108 (9.7) 12 (8.0) - 
         1 198 (13.0) 150 (13.5) 15 (10.0) - 
       >2 1169 (77.0) 855 (76.8) 123 (82.0) - 
 
  a Based on National Health Survey 2014-15 of the Australian Bureau of Statistics (> 18 years old); b  Excluded those who ticked “unsure” (n = 68) and those who 
did not specify their MS onset type (n = 187);  c Includes relapsing remitting multiple sclerosis and secondary progressive multiple sclerosis; d Includes primary 
progressive multiple sclerosis and progressive relapsing multiple sclerosis. 






Table 2. Prevalence of comorbidities of people with MS between symptom onset and at the 
time of study  
Comorbidity 











Depression 240 15.8 648 42.7 26.9 
Anxiety 242 15.9 592 39.0 23.1 
Allergies 443 29.2 568 37.4 8.2 
Hypertension 126 8.3 458 30.2 21.9 
Migraine 307 20.2 426 28.1 7.8 
High cholesterol 109 7.2 357 23.5 16.3 
Osteoarthritis 93 6.1 353 23.3 17.1 
Eye diseases 41 2.7 217 14.3 11.6 
Cancer 55 3.6 211 13.9 10.3 
Anaemia 110 7.2 202 13.3 6.1 
Osteoporosis 26 1.7 192 12.6 10.9 
Psoriasis 80 5.3 137 9.0 3.8 
Hypothyroidism 51 3.4 120 7.9 4.5 
Heart troubles b 26 1.7 105 6.9 5.2 
Type 2 diabetes 7 0.5 74 4.9 4.4 
Other autoimmune disorders 28 1.8 68 4.5 2.6 
Hyperthyroidism 16 1.1 45 3.0 1.9 
Rheumatoid arthritis 13 0.9 44 2.9 2.0 
Inflammatory bowel disease 18 1.2 39 2.6 1.4 
Peripheral vascular disease 10 0.7 35 2.3 1.6 
Stroke 6 0.4 34 2.2 1.8 
Myocardial infarction 4 0.3 30 2.0 1.7 
Epilepsy 12 0.8 26 1.7 0.9 
Coeliac disease 7 0.5 22 1.4 1.0 
Chronic renal disease 4 0.3 20 1.3 1.1 
Bipolar disorder 9 0.6 19 1.3 0.7 
Systemic lupus erythematosus 5 0.3 16 1.1 0.7 
Type 1 diabetes 11 0.7 15 1.0 0.3 
Schizophrenia 3 0.2 4 0.3 0.1 
Parkinson's disease 1 0.1 2 0.1 0.1 
 
a Absolute change (%) = prevalence at the time of study minus prevalence at symptom onset; b Heart troubles include angina, congestive heart 
failure and coronary artery disease. Values in bold font indicate >5% absolute change. 




Figure 1. Age-and-sex adjusted prevalence ratios of comorbidities of people with MS compared to the general Australian populationa 
at the time of study 
a Based on National Health Survey 2014-15 of the Australian Bureau of Statistics (> 18 years old).  
Gastrointestinal disorders include inflammatory bowel disease and coeliac disease. 
Heart disease, stroke and vascular disease include heart trouble (angina, congestive heart failure, coronary artery disease), myocardial infarction, stroke, cerebrovascular disease and peripheral vascular diseases.  
Thyroid disorders include hypothyroidism, hyperthyroidism and other thyroid disorders. 
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Table 3. Prevalence of comorbidities in people with relapse-onset MS compared to progressive-onset MS, with prevalence ratios calculated for 
comorbidities with >10 people. 
Comorbidity 
At MS symptom onset 
 
At the time of study 
Total, n (%) 
 
PRb (95% CI) Total, n (%) 
 














Crude Age and sex adjusted 
Depression 170 (16.5) 22 (16.4) 0.99 (0.64-1.55) 0.99 (0.61-1.62) 469 (42.6) 58 (39.5) 0.93 (0.71-1.22) 0.97 (0.73-1.29) 
Anxiety 177 (17.2) 25 (18.7) 1.08 (0.71-1.65) 0.88 (0.55-1.39) 419 (38.1) 60 (40.1) 1.07 (0.82-1.41) 0.82 (0.62-1.09) 
Allergy 349 (33.9) 34 (25.4) 0.75 (0.53-1.06) 1.32 (0.91-1.93) 445 (40.4) 39 (26.5) 0.66 (0.47-0.91) 1.51 (1.07-2.14) 
Hypertension 94 (9.1) 13 (9.7) 1.06 (0.59-1.90) 0.65 (0.39-1.10) 338 (30.7) 47 (32.0) 1.04 (0.77-1.41) 1.20 (0.87-1.65) 
Migraine 227 (22.1) 25 (18.7) 0.85 (0.56-1.30) 1.11 (0.70-1.76) 322 (29.3) 30 (20.4) 1.25 (0.95-1.64) 1.18 (0.80-1.74) 
High cholesterol 77 (7.5) 14 (10.5) 1.40 (0.79-2.47) 1.36 (0.68-2.72) 254 (23.1) 47 (32.0) 1.39 (1.02-1.89) 0.93 (0.67-1.29) 
Osteoarthritis 66 (6.4) 13 (9.7) 1.51 (0.83-2.74) 0.95 (0.48-1.87) 258 (23.4) 39 (26.5) 1.13 (0.81-1.59) 1.04 (0.73-1.47) 
Eye diseases 26 (2.5) 8 (6.0) - - 154 (14.0) 33(22.5) 1.61 (1.10-2.34) 0.91 (0.61-1.35) 
Cancer 38 (3.7) 7 (5.2) - - 151 (13.7) 24 (16.3) 1.19 (0.77-1.83) 0.97 (0.62-1.53) 
Anaemia 82 (8.0) 8 (6.0) - - 151 (13.7) 14 (9.5) 0.69 (0.40-1.20) 1.45 (0.81-2.59) 
Osteoporosis 17 (1.7) 4 (3.0) - - 129 (11.7) 26 (17.7) 1.51 (1.01-2.30) 0.84 (0.54-1.29) 
Psoriasis 64 (6.2) 7 (5.2) - - 103 (9.4) 13 (8.8) 0.95 (0.53-1.68) 1.02 (0.56-1.86) 
Hypothyroidism 39 (3.8) 5 (3.7) - - 91 (8.3) 9 (6.1) - - 
Heart troublesa 19(1.9) 5 (3.7) - - 73 (6.6) 17 (11.6) 1.74 (1.03-2.96) 0.98 (0.56-1.72) 
Type 2 diabetes 4 (1.1) 3 (2.2) - - 52 (4.7) 9 (6.1) - - 
Other autoimmune 
disorders 19 (1.9) 2 (1.5) 
- - 53 (4.8) 4 (3.0) - - 
Hyperthyroidism 11 (1.1) 2 (1.5) - - 32 (2.9) 4 (3.0) - - 
Rheumatoid arthritis 10 (1.0) 2 (1.5) - - 30 (2.7) 7 (4.8) - - 





disease 13 (1.3) 3 (2.2) - 
- 34 (3.1) 3 (2.1) - - 
Peripheral vascular 
disease 7 (0.7) 2 (1.5) 
- - 26 (2.4) 5 (3.4) - - 
Stroke 6 (0.6) 0 (0.0) - - 25 (2.3) 4 (3.0) - - 
Myocardial infarction 2 (0.2) 2 (1.5) - - 18 (1.6) 7 (4.8) - - 
Epilepsy 8 (0.8) 2 (1.5) - - 19 (1.7) 3 (2.0) - - 
Coeliac disease 6 (0.6) 0 (0.0) - - 16 (1.5) 2 (1.4) - - 
Chronic renal disease 4 (0.4) 0 (0.0) - - 18 (1.6) 1 (0.7) - - 
Bipolar disorder 3 (0.3) 1 (0.1) - - 12 (0.1) 2 (1.4) - - 
Systemic lupus 
erythematosus 5 (0.5) 0 (0.0) 
- - 14 (0.3) 2 (1.4) - - 
Type 1 diabetes 10 (1.0) 1 (0.1) - - 13 (0.2) 1 (0.7) - - 
Schizophrenia 1 (0.1) 1 (0.1) - - 1 (0.1) 2 (1.4) - - 
Parkinson's disease 0 (0.0) 0 (0.0) - - 1 (0.1) 0 (0.0) - - 
 
Abbreviations: PR = Prevalence ratio; 95% CI = 95% confidence interval 
a Heart troubles include angina, congestive heart failure and coronary artery disease. 
b Analysis was only performed for comorbidities with at least 10 participant counts. 
Values in bold font denote statistical significance at 95% confidence interval (CI). 










Progressive-onset MS  
p-value for 
interactiong Crude PR (95% CI)f 
Age and Sex adjusted 
PR 
(95% CI)f 
Crude PR (95% CI)f 
Age and Sex adjusted 
PR 
(95% CI)f 
Anaemia 6.41 (5.47-7.52) 5.06 (4.31-5.94) 4.45 (2.64-7.52) 5.20 (3.02-8.95) 0.08 
Cancer 6.05 (5.16-7.10) 4.48 (3.81-5.27) 7.21 (4.83-10.75) 3.87 (2.57-5.83) 0.47 
Depression 3.89 (3.55-4.26) 3.15 (2.88-3.45) 3.60 (2.79-4.66) 3.20 (2.47-4.13) 0.72 
Anxiety 3.56 (3.24-3.92) 3.13 (2.84-3.44) 3.82 (2.97-4.92) 3.80 (2.95-4.91) 0.47 
Migraine 3.80 (3.40-4.24) 3.09 (2.77-3.45) 2.65 (1.85-3.79) 2.90 (2.02-4.18) 0.20 
Psoriasis 2.84 (2.34-3.45) 2.45 (2.01-2.98) 2.69 (1.56-4.63) 2.29 (1.33-3.94) 0.88 
Epilepsy 2.58 (1.65-4.05) 2.29 (1.46-3.58) 3.06 (0.98-9.48) 3.04 (0.98-9.42) - 
Gastrointestinal disordersb 2.66 (2.00-3.54) 2.09 (1.57-2.79) 2.12 (0.88-5.09) 1.81 (0.75-4.34) - 
High cholesterol  2.52 (2.23-2.85) 1.79 (1.58-2.02) 3.50 (2.63-4.65) 1.77 (1.32-2.36) 0.78 
Hypertension 2.10 (1.89-2.33) 1.57 (1.41-1.75) 2.19 (1.64-2.91) 1.11 (0.83-1.48) 0.06 
Osteoporosis 2.61 (2.19-3.10) 1.45 (1.21-1.72) 3.94 (2.68-5.78) 1.96 (1.34-2.88) 0.80 
Heart disease, stroke and vascular 
diseasesc 1.59 (1.33-1.90) 1.36 (1.13-1.63) 2.124 (1.47-3.40) 1.17 (0.77-1.17) 0.73 
Thyroid disordersd 2.35 (1.97-2.82) 1.28 (1.06-1.53) 1.64 (0.91-2.97) 1.03 (0.57-1.85) 0.13 
Osteoarthritis 2.00 (1.77-2.26) 1.17 (1.04-1.32) 2.27 (1.66-3.10) 1.07 (0.78-1.48) 0.22 
Type 1 diabetes mellitus 1.50 (0.87-2.58) 1.17 (0.68-2.01) 0.86 (0.12-6.11) 0.56 (0.08-3.97) - 
Chronic renal disease 1.48 (0.93-2.35) 1.13 (0.71-1.80) 0.62 (0.09-4.38) 0.36 (0.05-2.56) - 
Other psychiatric disorderse 1.21 (0.70-2.09) 0.90 (0.52-1.55) 2.80 (1.05-7.45) 2.61 (0.98-6.95) - 
Rheumatoid arthritis 1.18 (0.83-1.69) 0.79 (0.55-1.14) 2.06 (0.98-4.33) 1.13 (0.54-2.36) - 
Type 2 diabetes mellitus 0.84 (0.64-1.10) 0.63 (0.48-0.83) 1.08 (0.56-2.08) 0.56 (0.29-1.07) - 
 
a Based on National Health Survey 2014-15 of the Australian Bureau of Statistics (> 18 years old); b Includes inflammatory bowel disease and coeliac disease; c Includes heart trouble (angina, congestive heart failure, coronary artery disease), 
myocardial infarction, stroke, cerebrovascular disease and peripheral vascular diseases;  d Includes hypothyroidism, hyperthyroidism and other thyroid disorders; e Includes bipolar disease, schizophrenia except depression and anxiety; f 95% CI 
= 95% confidence interval;  g p-values for MS onset type interaction were only calculated for comorbidities with 10 or more participant counts.  Values in bold font denote statistical significance at 95% confidence interval (CI). 
